Try our beta test site
11398 studies found for:    NCI
Show Display Options
Rank Status Study
21 Not yet recruiting Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Talimogene Laherparepvec
22 Not yet recruiting Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
Condition: Colorectal Adenoma
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration
23 Not yet recruiting Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Conditions: Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
24 Recruiting Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer;   Stage I Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
25 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
26 Not yet recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Conditions: Leiomyosarcoma;   Liposarcoma;   Sarcoma Differentiation Score 2;   Sarcoma Differentiation Score 3;   Stage IA Soft Tissue Sarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIA Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Biological: Talimogene Laherparepvec
27 Recruiting Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Recurrent Cervical Carcinoma;   Stage IV Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
28 Recruiting Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Conditions: Rectal Adenocarcinoma;   Stage II Rectal Cancer;   Stage III Rectal Cancer
Interventions: Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Veliparib
29 Not yet recruiting ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Conditions: Oral Cavity Neoplasm;   Oropharyngeal Neoplasm;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oral Cavity Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet;   Other: Pharmacological Study;   Other: Placebo
30 Not yet recruiting Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
Conditions: Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Microsatellite Instability;   Stage IIIA Colon Cancer;   Stage IIIB Colon Cancer;   Stage IIIC Colon Cancer
Interventions: Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
31 Not yet recruiting Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
32 Recruiting Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma
Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Panobinostat;   Other: Pharmacological Study
33 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Malignant Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
34 Recruiting Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Conditions: Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Recurrent Pancreatic Neuroendocrine Carcinoma
Intervention: Drug: Sapanisertib
35 Suspended Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
36 Recruiting FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
37 Not yet recruiting Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Chimerism;   Hematopoietic Cell Transplantation Recipient;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Decitabine;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
38 Not yet recruiting Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Conditions: Recurrent Colorectal Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Biological: Tremelimumab
39 Not yet recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Atezolizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Procedure: Lumpectomy;   Procedure: Mastectomy;   Drug: Paclitaxel
40 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.